Announcement from Acarix’s extra general meeting
The extra general meeting of Acarix AB ("Acarix" or the "Company") was held today on 9 December 2022 and the following resolutions were...
Acarix to present at the 2022 Nordic American Life Science Conference
Acarix, a leader acoustic and AI-based cardiac diagnostics announces that the company will present at the 7th Annual Nordic American Li...
Notice of Extra General Meeting in Acarix AB
The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Fr...
Acarix resolves on a partially guaranteed rights issue of approximately SEK 52.9 million
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, A...
Acarix presents at Redeye Life Science Day 2022
On November 24th at 14.50 CET Helen Ljungdahl Round, CEO of Acarix, will discuss the latest developments in the company in an in-depth ...
Full focus on the US market with strong interest from healthcare providers, reimbursement code in place and collaboration with ACC
Acarix is now taking an important strategic step, putting full commercial focus on the US market. We have the key building blocks in pl...
Invitation to presentation of Acarix´s third quarter report 2022
Acarix will publish its third quarter results on Wednesday 16 November 2022 at 08.00 am (CEST). A live webcast will be held at 16.30 (C...
Patient enrollment completed in the FILTER-SCAD randomized controlled multi-center trial
The FILTER-SCAD study is a randomized controlled clinical trial including more than 2,000 patients with suspected coronary artery disea...
Acarix and the American College of Cardiology announce strategic collaboration
The American College of Cardiology (“ACC”) and Acarix have signed a strategic collaboration agreement with the goal to deve...
Acarix presents at the Redeye event, Theme: Diagnostics
On September 27 at 11.30 am CEST, Helen Ljungdahl Round, President and CEO at Acarix will present the company´s latest developmen...
Acarix AB (publ) publishes Interim Report, January – June 2022
Significant interest and positive developments in the US marketWe can now conclude that our Go-To-Market strategy in the USA has starte...
Invitation to presentation of Acarix´s second quarter report
Acarix will publish its second quarter results on Thursday 25 August 2022 at 08.00 am (CEST). A live webcast will be held at 14.00 (CES...